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Following the outbreak of COVID-19, multidisciplinary research focusing on the long-term
effects of the COVID-19 infection and the complete recovery is still scarce. With
regards to long-term consequences, biomarkers of physiological effects as well
as the psychological experiences are of significant importance for comprehensively
understanding the complete COVID-19 recovery. The present research surveys the
IgG antibody titers and the impact of COVID-19 as a traumatic experience in the
aftermath of the active infection period, around 2 months after diagnosis, in a subset
of COVID-19 patients from the first wave (March-April 2020) of the outbreak in Northern
Cyprus. Associations of antibody titers and psychological survey measures with baseline
characteristics and disease severity were explored, and correlations among various
measures were evaluated. Of the 47 serology tests conducted for presence of IgG
antibodies, 39 (83%) were positive. We identified trends demonstrating individuals
experiencing severe or critical COVID-19 disease and/or those with comorbidities
are more heavily impacted both physiologically and mentally, with higher IgG titers
and negative psychological experience compared to those with milder disease and
without comorbidities. We also observed that more than half of the COVID-19 cases
had negative psychological experiences, being subjected to discrimination and verbal
harassment/insult, by family/friends. In summary, as the first study co-evaluating immune
response together with mental status in COVID-19, our findings suggest that further
multidisciplinary research in larger sample populations as well as community intervention
plans are needed to holistically address the physiological and psychological effects of
COVID-19 among the cases.
Keywords: COVID-19, SARS-CoV-2, recovery, immune response, antibody, psychological impact, stigma,
long COVID
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INTRODUCTION
Coronavirus disease of 2019 (COVID-19), resulting from SARS-
CoV-2 infection, was declared a pandemic by the World
Health Organization on 11 March 2020. As of 29 July 2020,
more than 16,000,000 COVID-19 cases were identified, and
more than 650,000 deaths were reported due to the disease
(1). Although the scientific community has responded rapidly
to detect the transmission mechanisms and develop vaccines,
multidisciplinary research focusing on the long-term effects of
the COVID-19 infection is still scarce, and not much is known
on how the human body responds to COVID-19 infection,
both biologically and psychologically during the “longer term
recovery” period after discharge from the hospital/isolation.
With regards to long-term effects, biomarkers of physiological
effects as well as the psychological experiences are of significant
importance for a comprehensive understanding of the COVID-
19 recovery period (2). COVID-19 as a life-threatening infection
can act as an acute stressor (3) and stress can have a down-
regulatory effect on the immune system (4). The present research
surveys the IgG antibody titers and the impact of COVID-19 as
a traumatic experience both during and in the aftermath of the
active infection period.
There is insufficient information on the immune response to
COVID-19 (e.g., prevalence of different antibodies against the
infection over time and development of long-term immunity). It
is essential to better understand the timeline of immune response
including the appearance of immunoglobulin M (IgM) and
immunoglobulin G (IgG) antibodies, their lifespan and whether
they are protective, at least partially, against a second infection.
Preliminary research shows that detectable IgG antibodies
generally start appearing after the 1st week after symptom
onset, reach a peak around 2–3 weeks, and stay at detectable
blood levels at least for a duration of 2–3 months even in
milder cases, similar to previous observations in other SARS
infections (5–7). Moreover, the psychological effects of having
the infection are also complex. The potential life-threatening
impact of having severe COVID-19, the overall disease burden,
along withmany unknowns about its short- and long-term effects
increase the stigma attached to the infection and the related
anxiety among the public. These factors, in turn, make COVID-
19 cases more vulnerable to post-traumatic stress as well as
targets for harassment and discrimination (8). It is presumed
that the period of complete physiological and psychological
recovery from the infection depends on disease severity and
other physiological and socioeconomic factors. However, given
all the elaborate aspects of COVID-19 yet to be investigated and
understood, themulti-faceted complete recovery period is still far
from being deciphered.
From a psychological point of view, initial findings suggest
that both the disease itself and the negative consequences of the
lockdown imposed by governments to curb the spread of the
disease could result in negative coping behavior which includes
but is not limited to panic, anxiety, stigmatization, and post-
traumatic stress disorder (PTSD) (3). As scarce research shows,
these reactions can also be influenced by contextual factors
such as a history of war, famine, natural disasters, man-made
accidents and the size of the population. More specifically, while
smaller nations might appear to have the upper hand in rapid
enforcement ofmeasures, contextual factors such as the increased
connectivity of the individuals in smaller societies, or negative
collective experiences of war and famine in the past might
increase the prevalence of negative coping behaviors and stigma
induced depression (9).
A particular case in point is Northern Cyprus, governed by a
state that remains internationally unrecognized, and hence, not
included in the global epidemiological COVID-19 statistics. In
the first wave of the COVID-19 outbreak in Northern Cyprus,
108 cases were diagnosed between 10 March and 16 April
2020. The authorities responded promptly and lockdown was
imposed on March 11 (9) effectively halting education and
government offices, and all other services except those considered
essential. In addition to the global concern over the pandemic,
the small community setting in Northern Cyprus (an estimated
total population of around 400,000) with a history of war and
trauma (10) further caused intensified anxiety and fear in an
already sensitive population. Panic engulfed the small nation
and there was widespread stigma toward those who tested
positive or considered high-risk for transmitting the disease,
i.e. Turkish Cypriots living abroad, who were brought home
and quarantined (11). Videos of individuals under duress as
a result of being quarantined were widely circulated in the
social media, and there were news of occasional small-scale
protests in neighborhoods where quarantine hotels were chosen
due to the perceived infection threat (12). Similarly, those who
were tested positive recounted psychological trauma as their
names made public and have been targeted (13). Therefore,
there are sufficient grounds to assume that in addition to the
physiological impact of the disease, those who tested positive
for the COVID-19 have also experienced psychological distress
during and after the active infection period. In fact, in an
earlier study conducted in Wuhan (China), the prevalence
of significant post-traumatic stress symptoms associated with
COVID-19 was estimated as 96.2% among clinically stable
COVID-19 cases at discharge from quarantine (14). Taken
together, these observations suggest that assessing the biological
markers of physiological effects vis-à-vis negative psychological
experiences of the COVID-19 cases is important for holistic
management of COVID-19 patients from diagnosis to potentially
complete physiological and psychological recovery. The present
research surveys the immune response (IgG antibody titers) and
negative psychological experiences among the COVID-19 cases




Participants and Study Design
We performed a joint investigation of the immune response and
mental status of the COVID-19 cases at an average time of 2
months after diagnosis. Within the scope of our study, these
two main outcomes of interest comprise the assessments toward
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the complete recovery of the cases. Of the 108 cases diagnosed,
32 were tourists on the island: two died with the disease, and
the remaining 30 individuals returned to their country after
discharge from hospital/isolation. Dependent on the severity
of the disease, COVID-19 cases were either monitored in the
hospital or isolation hotels designated by the health authority.
Of the remaining 76 individuals residing in Northern Cyprus,
two died with the disease. A total of 74 individuals were invited
to participate in the post-discharge assessment of antibody
development and psychological impact. For the psychological
evaluation, eight individuals under the age of 18 as well as three
individuals who did not speak Turkish or English fluently were
excluded from the study. Hence, a total of sixty-three individuals
were eligible to participate in the psychological evaluation.
All subjects were informed about both components of the
study, provided informed consent acknowledging voluntary
participation, option to withdraw from study at any time, and
the confidentiality of their antibody results and their responses
to the survey.
Eligibility Criteria
General Inclusion Criteria: Confirmed (i.e., with positive
polymerase chain reaction test result) COVID-19 infection in
Northern Cyprus between the dates of 10 March – 17 April and
residence in northern Cyprus.
Exclusion Criteria for Antibody Development Analysis: Refusal
to give informed consent, or contraindication to venipuncture.
Exclusion Criteria for Psychological Survey: Refusal to give
informed consent, inability to understand/speak Turkish or
English fluently, or being under the age of 18.
Blood Collection and Transfer
Blood samples were taken by trained nurses during home visits.
Venipuncture was used to collect blood. 10mL complete gel
barrier formation tubes were used for blood collection (See
Supplementary Text for the details).
Serology Testing
The Abbott SARS-CoV-2 IgG assay is a chemiluminescent
microparticle immunoassay (CMIA) intended for both the
quantitative and qualitative detection of IgG antibodies to the
nucleocapsid protein of SARS-CoV-2 in human blood serum and
plasma. Assay specifications indicate that the SARS-CoV-2 IgG
assay is intended for use as an aid in identifying individuals
with an adaptive immune response to SARS-CoV-2, indicating
recent or prior infection. This assay is only for use under
the United States Food and Drug Administration’s Emergency
Use Authorization. Per the assay’s recommended definition, we
defined positive IgG response in the study as a titer level ≥
1.4 index signal/cutoff (s/co) (15). Assays were run on Abbott’s
ARCHITECTPlus i2000SR System.
The reported positive predictive agreement (PPA) for
the assay at ≥14 days post-symptom onset was 100.0%
(95% confidence-interval (CI): 95.9–100%) while the negative
predictive agreement (NPA) was 99.6% (95% CI: 99.1–99.9%).
Performance characteristics of the assay were independently
evaluated in a study conducted in Boise, Idaho, where specificity
and sensitivity were reported as 99.90 and 100% (starting at day
17 after symptom onset), respectively (16).
Psychological Measures
We designed a questionnaire-based survey to assess the negative
psychological experiences of the cases. Whenever possible, we
adapted and used tested and validated measures for known
psychological processes. More specifically, we assessed the extent
of experiencing COVID-19 as a life changing trauma (CALCT),
negative emotions, perceived importance of preventive measures,
awareness and habits, initial reaction to diagnosis, evaluation of
general health, stigma, perceived discrimination, post-traumatic
anxiety, and evolving perspectives after discharge via the survey
response measures. Ordinal response scales with five levels (with
corresponding scores of 1–5) were used for each measure.
Multiple measures on the same psychological process were
combined to create one composite scale process measure by
computing the average score per individual. Higher computed
scores indicated stronger experience of COVID-19 as a life
changing trauma, perceived higher importance of preventive
measures, stronger initial reaction to diagnosis, more positive
evaluation of general health, more perceived discrimination,
higher post-traumatic anxiety, and stronger anticipation of future
COVID-19 related anxiety.
We verified the internal reliability of our multi-item process
measures via Chronbach’s alpha (α > 0.70). Experiencing
COVID-19 as a life-changing trauma was measured with three
items (α = 0.84) adapted from (17). Negative emotions during
the recovery were assessed by four items (α = 0.79). Perceived
discrimination on the basis of being COVID-19 positive was
measured by six items (α = 0.90) adapted from (18). We also
measured anxiety related to anticipated stigma in the future as
a result of COVID-19 diagnosis with two items (α = 0.82). We
measured subjective evaluation of health before the diagnosis
and after the discharge with a single item each. Willingness to
help others by sharing information was measured by a single
item and perceived importance of protective measures by four
items (α = 0.96). Full list of the items can be found in the
Supplementary Material - Psychological Survey.
Statistical Analysis
Analysis of quantitative IgG titers and CALCT psychological
process scores was conducted via non-parametric tests: Wilcoxon
rank-sum test (for factors with two levels) andKruskal-Wallis test
(for factors with three or more levels). Due to small group sample
sizes, these rank-based non-parametric tests that do notmake any
assumptions regarding the underlying distribution of the data
were preferred for group comparisons (19, 20). We computed
descriptive statistics for the socio-demographics factors and
summary measures [mean score (M) with standard deviation
(SD)] for psychological processes, and conducted Pearson
correlation tests to explore whether the selected psychological
processes were associated with each other. All single-item survey
questions and multi-item process measures use five-point Likert
scales (one lowest, five highest) and have a mid-level at 2.5.
Disease severity was defined as critical (requiring intensive care),
severe (requiring oxygen therapy, but otherwise stable) and
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TABLE 1 | Baseline characteristics and disease severity by endpoint.
Serology (N = 47) Psychological survey (N = 41)a
Sex Women 28 (60%) 23 (56%)
Men 19 (40%) 18 (44%)
Age 0–29 9 (19%) 7 (17%)
30–59 25 (53%) 21 (51%)
60+ 13 (28%) 13 (32%)
Education Completed Elementary School 11 (23%) 10 (24%)
Middle/High School 15 (32%) 13 (32%)
University or Higher 18 (38%) 18 (44%)
Not Reported 3 (6%)
Any Symptom Reported at the Time of Diagnosis No 10 (21%) 8 (20%)
Yes 37 (79%) 33 (80%)
Fever/History of Fever Reported at the Time of Diagnosis No 25 (53%) 23 (56%)
Yes 22 (47%) 18 (44%)
Comorbidityb No 32 (68%) 28 (68%)
Yes 15 (32%) 13 (32%)
Disease Severityc Mild/Moderate 38 (81%) 33 (80%)
Severe/Critical 9 (19%) 8 (20%)
aOf the 47 individuals who provided blood samples for serology testing, four cases were not invited to respond to the survey (one <18 years old, and three not fluent in local language)
and two declined to participate in the survey.
bMost frequently reported chronic diseases were hypertension (N = 9) and diabetes (N = 5, two with concurrent hypertension).
cDisease severity was defined as critical (requiring intensive care), severe (requiring oxygen therapy, but otherwise stable) and mild/moderate (all other cases including
asymptomatic cases).
mild/moderate (all other cases). P-values <0.001 were displayed
as “p < 0.001.” Statistical significance was defined as p < 0.05.
Multivariate analyses were not carried out due to small sample




Of the 74 cases eligible for serology testing, 47 (64%; 60% women
and 40%men) accepted the invite and provided blood for testing.
Median [interquartile range (IQR)] time from initial COVID-19
diagnosis to blood draw for serology testing was 66 [63.5–73]
days with min-max of 50–86 days. Of the 63 cases eligible for
responding to the psychological survey, 41 (65%) responded to
survey questions (Table 1).
For the serology testing, 19% were <30 years of age, 53%
were between 30 and 60 years old, and 28% were ≥60 years of
age. At the time of COVID-19 diagnosis, 79 and 47% of the
serology analysis participants reported “at least one symptom”
and “fever history,” respectively. Thirty-two percent had at
least one comorbidity – most frequently hypertension (N =
9) and diabetes (N = 5, two with concurrent hypertension).
COVID-19 disease severity was severe or critical for 9 (19%)
cases and mild/moderate for the remaining 38 (81%). For the
psychological survey, distributions of participant baseline and
disease severity characteristics were similar to those of the blood
serology analysis (Table 1). Detailed cross-tabulation of baseline
characteristics and disease severity by age group is displayed in
Supplementary Table 1.
Serology
Of the 47 serology tests conducted for IgG antibody development,
39 (83%) were positive and 8 (17%) were negative. All of the
negative results came from individuals who experienced
mild/moderate disease. Overall median [IQR] titer level
was 4.38 [2.05–5.88]. Median [IQR] titer level among
positives and negatives were 4.95 [3.79–6.09], and 0.61
[0.16–0.72], respectively.
Figure 1 and Supplementary Table 2 display the distribution
of IgG antibody titers by baseline characteristics and disease
severity. The factor that had the most impact on IgG titer at
a median follow-up of 2 months post-diagnosis was disease
severity. Nine subjects who had severe/critical disease had
median [IQR] IgG titer of 6.09 [5.88–6.24] vs. 3.94 [1.70–5.52]
reported for thirty-eight subjects with mild/moderate disease
(Wilcoxon rank-sum test; p= 0.001). Among the baseline factors,
fever/history of fever reported at the time of diagnosis yielded
median [IQR] IgG titer of 5.56 [4.11–6.20] vs. 3.57 [1.47–5.13]
reported for those without fever/history of fever (Wilcoxon
rank-sum test; p = 0.01). Having a comorbidity also produced
higher median [IQR] IgG titers of 5.52 [4.31–6.09] vs. 3.87
[1.25–5.56] in those without a comorbidity (Wilcoxon rank-sum
test; p= 0.03).
The distributions of IgG titers by cross-tabulation of
baseline characteristics and disease severity are displayed in
Supplementary Table 3. In the mild/moderate disease severity
group, a significantly higher level of IgG titer was observed in
individuals with comorbidities (median [IQR]: 5.02 [3.92–5.67])
compared to those without (median [IQR]: 3.43 [0.88–4.87])
(Wilcoxon rank-sum test; p= 0.03).
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FIGURE 1 | IgG Levels Overall, by Baseline Factors and Disease Severity. IgG levels were measured at a median [IQR] time of 66 [63.5–73] days from initial COVID-19
diagnosis. See Supplementary Table 2 for detailed summary statistics. Mod, Moderate; Sev, Severe.
TABLE 2 | Descriptive statistics and correlations between the measured psychological processes.
Process M SD 1 2 3 4 5 6 7 8
1. COVID-19 as Life-changing Trauma (CALCT) 3.17 1.41
2. Negative Emotions 2.61 1.25 0.54**
3. Perceived Discrimination 2.48 1.30 0.54** 0.24ns
4. Global Health before Diagnosis 4.45 0.72 −0.02ns −0.07ns 0.09ns
5. Global Health after Diagnosis 4.21 0.83 −0.15ns −0.20ns −0.17ns 0.42**
6. Pro-social Tendencies 4.39 0.97 0.25ns 0.28ns 0.18ns −0.20ns −0.16ns
7. Perceived Importance of Protective Measures 4.42 1.00 0.24ns 0.09ns 0.09ns 0.14ns −0.12ns 0.41**
8. Future Stigma Related Anxiety 1.99 1.06 0.54** 0.05ns 0.80** −0.07ns −0.06ns 0.13ns −0.02ns
M, Mean; SD, Standard Deviation.
Standardized coefficients are shown. A psychological process score for a participant reflects the corresponding average score of the survey responses (in the ordinal scale of 1–5)
used to measure that psychological process. Higher computed score indicated stronger experience of COVID-19 as a life changing trauma, perceived higher importance of preventive
measures, stronger initial reaction to diagnosis, more positive evaluation of general health, more perceived discrimination, higher post-traumatic anxiety, or stronger anticipation of future
COVID-19 related anxiety.
**p < 0.001; ns, non-significant (p ≥ 0.05).
Negative Psychological Experiences
We report the descriptive statistics and the associations between
negative psychological processes in Table 2.
Perception of COVID-19 diagnosis as a life changing
traumatic event revealed a mean score of 3.17 [SD 1.41], which is
above the mid-level. Figure 2 displays the distribution of CALCT
scores by baseline characteristics and disease severity. Similar to
the IgG titer analysis, the factors that have shown trends for the
most impact on CALCT scores at amedian follow-up of 2months
post-diagnosis was disease severity, followed by presence of a
comorbidity. Mean (SD) CALCT scores in mild/moderate and
severe/critical disease groups were 3.01 (1.38) and 3.95 (1.42),
respectively (Wilcoxon rank-sum test; p = 0.10). For individuals
with a comorbidity, mean (SD) CALCT score was 3.53 (1.48) as
compared to 3.02 (1.39) in those without (Wilcoxon rank-sum
test; p= 0.30).
Among the individual questions measuring the negative
psychological experiences, 24 (59%) respondents indicated a
change in their perspective on life and their priorities due
to the COVID-19 infection. All 6 (100%) responders to the
question with severe/critical disease and 18 out of 33 (55%)
responders with mild/moderate disease indicated a change in
their perspective on life and their priorities due to the COVID-
19 infection. Nineteen (46%) individuals indicated that they have
become a more worried/anxious person because of the infection,
and 20 (49%) perceived the infection period as a turning point in
their lives (42 and 75% of the individuals withmild/moderate and
severe/critical disease, respectively) (Supplementary Table 4).
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FIGURE 2 | COVID-19 as Life-changing Trauma (CALCT) Scores Overall, by Baseline Factors and Disease Severity. Psychological measures were assessed around 2
months from initial COVID-19 diagnosis. See Supplementary Table 4 for distribution of responses to the three CALCT survey items. Mod, Moderate; Sev, Severe.
The mean score for the negative emotions due to COVID-
19 diagnosis was 2.61 (SD 1.25) and also above the mid-level of
the scale (2.5). As for the individual emotions, felt as an initial
reaction to COVID-19 diagnosis, worry ranked the first with
71% of respondents having felt it moderately, a lot or quite a
lot, followed by helplessness (47%), fear of death (31%) and guilt
due to not being sufficiently self-protected (19%). Fear of death
and helplessness were both reported moderately or above by 27%
and 50% of individuals in the mild/moderate and severe/critical
disease severity groups, respectively (Supplementary Table 5).
Additional analyses of our psychological measures revealed
that perceiving COVID-19 as a life changing trauma is strongly
and positively associated with experiencing negative emotions
(r = 0.54, p < 0.001), perceived discrimination (r = 0.54, p <
0.001); and future stigma related anxiety (r = 0.54, p < 0.001).
Similarly, perceived importance of protective measures is again
strongly and positively associated with pro-social tendencies (r=
0.41, p < 0.001). Last but not least, perceived discrimination at
present is strongly and positively associated with future stigma
related anxiety (r = 0.80, p < 0.001) (Table 2).
CONCLUSIONS
We detected IgG antibodies in 39 (out of 47; 83%) of cases after
a median of 66 days, which was a considerably longer follow-up
period compared to the previous serological studies on IgG (on
average up to ∼30 days; 21–23). This observation confirms that
IgG antibodies are still detectable in the blood in most COVID-
19 cases around 2 months post-diagnosis. However, further
studies are necessary to determine the neutralizing activity
of these antibodies and whether they provide any immunity
against a second infection. Moreover, severe/critical COVID-19
cases most of whom were older and/or with comorbidities had
higher IgG titers, and also showed trends for the most impact
mentally. Overall, we conclude that more specialized attention
should be paid to this group for providing further monitoring
and treatment post-discharge because of their higher healthcare
needs related to comorbidities as well as the psychological impact
in order to expedite the full recovery period after the infection.
Our analyses replicated the previous observations that disease
severity is an important predictor of blood IgG levels (21–
23), and confirmed that this observation holds true in the
longer follow-up period we examined. Furthermore, among
individuals with mild or moderate disease, we observed that
those with comorbidities had significantly higher IgG levels
(Supplementary Table 3). Similarly, Liu et al. observed that
besides the severe COVID-19 cases who tended to have a more
vigorous IgG response, a subset of the cases with mild disease
had a robust IgG antibody response, and suggested that age
and comorbidities may impact the timing and magnitude of the
immune response (23). Fever reported at the time of diagnosis
also hinted at a possible association with post-discharge IgG
levels, but studies with larger case numbers are needed to evaluate
these potential predictors of IgG levels with respect to potential
confounders such as age, sex, different types of co-morbidities
(e.g., autoimmune and endocrine-related diseases) and disease
severity via multivariate models. All these factors with potential
association to higher IgG titers are correlated with each other,
and reflect increased disease burden during diagnosis and post-
discharge (Supplementary Table 1). It is known that severity of
COVID-19 is associated with a dysregulated immune response,
and hence, further investigation of how dysregulated immune
response is reflected in the long-term blood antibody levels may
provide insights into the biological mechanism of the disease
and support development of effective vaccines that are based on
long-term immune response (24, 25).
In line with previous research, one in every two individuals
with severe/critical disease felt fear of death and helplessness
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while one in every four individuals with mild/moderate disease
felt these two emotions. Worry was the most commonly
expressed emotion among the four negative emotions queried,
with 71% of respondents having felt it moderately or more
(Supplementary Table 5). Based on the responses to the
psychological survey about 2months after diagnosis, we infer that
most cases have not yet recovered from the mental impact of the
disease. Participants experienced COVID-19 as a life-changing
trauma, experienced negative emotions, perceived themselves as
discriminated against and experienced anxiety due to anticipated
stigma in the future. In addition to replicating previous research
on the negative psychological consequences of being tested
positive for an infectious disease and that pandemics have a
lasting negative impact on mental health among the general
population (26–28), our findings also show that a subset of cases
experienced anxiety as a result of anticipated stigma. This is a
novel finding which reveals that pandemics like COVID-19 have
long-term negative mental health effects. Future research could
replicate and extend these findings via longitudinal designs.
Post-traumatic stress is an important part of this disease due
to its overall severity, global impact and stigma attached to it.
About half of the survey respondents reported being a more
worried person due to the infection, and perceiving the infection
as a turning point in their life. About one in four individuals
also reported concern that their relationship with their workplace
and family/friends will deteriorate due to infection. Hence,
community resources for provision of psychological support
to the COVID-19 cases post-discharge is very important to
minimize the long-term impact of the disease and maintain
mental health in these individuals. InNorthern Cyprus, a number
of organizations and universities have already taken action and
set up psychological counseling hotlines, free for use by the public
(9). These initiatives are very important and need to be expanded
throughout the countries, regions and globally. However, more
tailored intervention programs are needed especially for COVID-
19 cases to combine mental check-ups with regular health check-
ups at regular intervals. About one in ten individuals thought
they could still transmit the disease. This provides another
example of importance of using up-to-date medical info about
the disease, and the person’s current status in providing tailored
therapy to the person for getting over pre-conceived notions
about fear of continuing disease in the individual.
Overall perception about the disease as a threat varied with
disease severity (Supplementary Table 12).Whilemore than half
of the cases with mild/moderate disease deemed the infection
was nothing to be afraid of, only one in four thought the same
among the severe/critical cases. Therefore, a consistent public
communication strategy is needed to ensure public perception of
the disease will not change over time from a conscious alertness
to the disease being “nothing to be afraid of” due to sharing of
experiences/perceptions by an estimated 80% of the cases in the
mild/moderate severity group among the community.
The study is subject to a number of limitations. Although our
study participation rates of 64% (serology) and 65% (psychology)
among discharged COVID-19 cases are acceptable for an
exploratory study such as this one, there may be some differences
between individuals willing and unwilling to participate in
the study, especially with respect to psychological endpoints.
Actually, we observed lower participation rates in the study by
cases from a rural region that was more severely impacted by
the outbreak and had to go under a regional quarantine for
an extended time. Disease stigma, continuing worry, suspicion
and mistrust likely led to lower participation rates, and these
factors are directly related to psychological endpoints studied
here. To facilitate a more practical implementation in the field,
it was not possible to use a consistent time point for evaluation
of the outcomes of interest. Nevertheless, timing of blood draw
and survey response showed limited variability around a 2-
month time point post-diagnosis, with median [IQR] and range
time being 66 [63.5–73] and 50–86 days, respectively. Due to
limited resources, it was not possible to conduct the study
longitudinally via multiple time points to evaluate trends in
further detail. There were possibly correlated responses for either
or both endpoints as we allowed participation of multiple family
or household members in the study. There were eight families
that were represented in the study with 2–3 members each.
Finally, compared to continuous IgG titer measures, categorical
nature of the survey responses produced higher variability
in calculated psychological process scores, and hence, lower
statistical power in detecting any associations with baseline
factors and disease severity.
Another major limitation of our study is absence of any
data collection on clinical signs, symptoms or measures that are
potentially associated with continuing recovery process. At the
time we conducted our study, little was known on the long-term
impact of COVID-19 and how it manifested in the cases. In
recent months, there has been evolving information regarding
numerous defined and undefined conditions associated with
COVID-19, including long-term organ damage, nervous
system damage and immune system dysregulations. The most
commonly reported general symptoms post acute COVID-19
have been fatigue and dyspnea, followed by joint pain and chest
pain. As part of the organ-specific dysfunction, myocardial
injury/inflammation has been detected via increased troponin
levels and cardiac magnetic resonance imaging, and pulmonary
dysfunction via radiologic abnormalities, decreased diffusion
capacity for carbon monoxide and diminished respiratory
muscle strength. The most common neurologic symptoms
reported have been headache, vertigo, anosmia and ageusia, with
encephalitis, seizures, major mood swings and “brain fog” also
having been reported (29). A refined and detailed assessment
of complete recovery process in future studies should include
monitoring for these conditions occurring mostly post-discharge
via their associated symptoms, laboratory test results and/or
medical imaging findings.
In conclusion, this is the first study jointly evaluating post-
discharge blood antibody levels and psychological status at
a median time of 2 months after diagnosis. Severe/critical
COVID-19 cases had higher blood IgG antibody levels as well
as the highest long-term mental impact. Holistic and a more
personalized approach is needed for post-discharge monitoring
and treatment of COVID-19 cases, with a focus on older age,
comorbidity status and disease severity. Recognizing the long-
term impact of the disease [coined as “long COVID” (30)],
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collaborating globally to accumulate detailed standardized long-
term psychological and physiological data (31) and continuing
to re-define and publicize the importance of complete recovery
are key in addressing the long-term health consequences of
COVID-19 via awareness, monitoring and timely intervention.
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13. Demir D. Dişlandik, hain ilan edildik. Yenidüzen (2020). Available
online at: http://www.yeniduzen.com/dislandik-hain-ilan-edildik-129610h.
htm (accessed July 29, 2020).
14. Bo H-X, Li W, Yang Y, Wang Y, Zhang Q, Cheung T, et al. Posttraumatic
stress symptoms and attitude toward crisis mental health services
among clinically stable patients with COVID-19 in China. Psychol Med.
(2020). doi: 10.1017/S0033291720000999. [Epub ahead of print].
15. Abbott ARCHITECT SARS-CoV-2 IgG instructions for use. H14806R01. (April
2020). Available online at: https://www.fda.gov/media/137383/download
(accessed July 29, 2020).
Frontiers in Public Health | www.frontiersin.org 8 February 2021 | Volume 8 | Article 590096
Barin et al. COVID-19: Physiological and Psychological Recovery
16. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A,
et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG
assay and seroprevalence in Boise, Idaho. J Clin Microbiol. (2020) 58:e00941–
20. doi: 10.1128/JCM.00941-20
17. García FE, Cova F, Rincón P, Vázquez C, Páez D. Coping, rumination and
posttraumatic growth in people affected by an earthquake. Psicothema. (2016)
28:59–65. doi: 10.7334/psicothema2015.100
18. Branscombe NR, Schmitt MT, Harvey RD. Perceiving pervasive
discrimination among African Americans: implications for
group identification and well-being. J Pers Soc Psychol. (1999)
77:135–49. doi: 10.1037/0022-3514.77.1.135
19. Wilcoxon F. Individual comparisons by ranking methods. Biom Bull. (1945)
1:80–3. doi: 10.2307/3001968
20. KruskalWH,WallisWA. Use of ranks in one-criterion variance analysis. J Am
Stat Assoc. (1952) 47:583–621. doi: 10.2307/2280779
21. Zhang G, Nie S, Zhang Z, Zhang Z. Longitudinal change of severe acute
respiratory syndrome coronavirus 2 antibodies in patients with coronavirus
disease 2019. J Infect Dis. (2020) 222:183–8. doi: 10.1093/infdis/jiaa229
22. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody
responses to SARS-CoV-2 in patients with COVID-19. Nat Med. (2020)
26:845–8. doi: 10.1038/s41591-020-0897-1
23. Liu X, Wang J, Xu X, Liao G, Chen Y, Hu C-H. Patterns of IgG and IgM
antibody response in COVID-19 patients. Emerging Microbes Infect. (2020)
9: 1269–74. doi: 10.1080/22221751.2020.1773324
24. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation
of immune response in patients with coronavirus 2019 (COVID-19)
in Wuhan, China. Clin Infect Dis. (2020) 71:762–8. doi: 10.1093/cid/
ciaa248
25. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional
exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).
Front Immunol. (2020) 11:827. doi: 10.1101/2020.02.18.20024364
26. Maunder R, Hunter J, Vincent L, Bennett J, Peladeau N, Leszcz M, et al. The
immediate psychological and occupational impact of the 2003 SARS outbreak
in a teaching hospital. Can Med Assoc J. (2003) 168:1245–51.
27. Serafini G, Parmigiani B, Amerio A, Aguglia A, Sher L, Amore M.
The psychological impact of COVID-19 on the mental health in
the general population. QJM. (2020) 113:531–7. doi: 10.1093/qjmed/
hcaa201
28. Wu P, Fang Y, Guan Z, Fan B, Kong J, Yao Z, et al. The psychological
impact of the SARS epidemic on hospital employees in China: exposure,
risk perception, and altruistic acceptance of risk. Can J Psychiatry. (2009)
54:302–11. doi: 10.1177/070674370905400504
29. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-
19. JAMA. (2020) 324:1723–4. doi: 10.1001/jama.2020.19719
30. Long COVID: let patients help define long-lasting COVID symptoms.Nature.
(2020) 586:170. doi: 10.1038/d41586-020-02796-2
31. University of Oxford. Global Consortium Launches New Study Into Long-
Term Effects of COVID-19. (2020). Available online at: https://www.ox.ac.
uk/news/2020-09-11-global-consortium-launches-new-study-long-term-
effects-covid-19 (accessed October 18, 2020).
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Barin, Yoldascan, Savaskan, Ozbalikci, Karaderi and Çakal. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Public Health | www.frontiersin.org 9 February 2021 | Volume 8 | Article 590096
